Zydus Cadila receives final approval from USFDA for Tranexamic Acid Injection

20 Jul 2017 Evaluate

Zydus Cadila has received the final approval from the USFDA to market Tranexamic Acid Injection, 1000 mg/10 mL (100 mg/mL) Single dose Vial. Tranexamic Acid Injection belongs to the class of medications called antifibrinolytic agents.

This medication is used to prevent or reduce bleeding in patients with haemophilia undergoing tooth extraction and will be produced at the group’s formulations manufacturing facility at Moraiya, in Ahmedabad.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group now has more than 130 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.


Zydus Lifesciences Share Price

881.95 -2.90 (-0.33%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×